Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Clinical Trial
. 2019 Dec;104(12):e555-e557.
doi: 10.3324/haematol.2018.214429. Epub 2019 Apr 4.

Myeloablative conditioning using timed-sequential busulfan plus fludarabine in older patients with acute myeloid leukemia: long-term results of a prospective phase II clinical trial

Rohtesh S Mehta  1 , Roland Bassett  2 , Amanda Olson  1 , Julianne Chen  1 , Sairah Ahmed  1 , Amin M Alousi  1 , Paolo Anderlini  1 , Gheath Al-Atrash  1 , Qaiser Bashir  1 , Stefan O Ciurea  1 , Chitra M Hosing  1 , Jin S Im  1 , Partow Kebriaei  1 , Issa Khouri  1 , David Marin  1 , Jeffrey J Molldrem  1 , Yago Nieto  1 , Betul Oran  1 , Katayoun Rezvani  1 , Muzaffar H Qazilbash  1 , Samer A Srour  1 , Elizabeth J Shpall  1 , Borje S Andersson  1 , Richard E Champlin  1 , Uday R Popat  3
Affiliations
Clinical Trial

Myeloablative conditioning using timed-sequential busulfan plus fludarabine in older patients with acute myeloid leukemia: long-term results of a prospective phase II clinical trial

Rohtesh S Mehta et al. Haematologica. 2019 Dec.
No abstract available

PubMed Disclaimer

Figures

Figure 1.
Figure 1.
Kaplan-Meier curves showing the impact of pre-hematopoietic cell transplantation (HCT) disease status on survival. (A) Overall survival and (B) progression-free survival; CI: Confidence Interval; CR: complete remission; MRD: measurable residual disease.
See this image and copyright information in PMC

References

    1. Popat UR, Mehta RS, Bassett R, et al. Fludarabine with a higher versus lower dose of myeloablative timed-sequential busulfan in older patients and patients with comorbidities: an open-label, non-stratified, randomised phase 2 trial. Lancet Haematol. 2018;5(11):e532–e542. - PMC - PubMed
    1. Dohner H, Estey E, Grimwade D, et al. Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel. Blood. 2017;129(4):424–447. - PMC - PubMed
    1. Sorror ML, Maris MB, Storb R, et al. Hematopoietic cell transplantation (HCT)-specific comorbidity index: a new tool for risk assessment before allogeneic HCT. Blood. 2005;106(8):2912–2919. - PMC - PubMed
    1. McClune BL, Weisdorf DJ, Pedersen TL, et al. Effect of age on outcome of reduced-intensity hematopoietic cell transplantation for older patients with acute myeloid leukemia in first complete remission or with myelodysplastic syndrome. J Clin Oncol. 2010;28(11):1878–1887. - PMC - PubMed
    1. Devine SM, Owzar K, Blum W, et al. Phase II Study of Allogeneic Transplantation for Older Patients With Acute Myeloid Leukemia in First Complete Remission Using a Reduced-Intensity Conditioning Regimen: Results From Cancer and Leukemia Group B 100103 (Alliance for Clinical Trials in Oncology)/Blood and Marrow Transplant Clinical Trial Network 0502. J Clin Oncol. 2015;33(35):4167–4175. - PMC - PubMed

Publication types

MeSH terms